507 related articles for article (PubMed ID: 19248044)
1. Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma.
Luminari S; Marcheselli L; Sacchi S; Pozzi S; Bari A; Ilariucci F; Stelitano C; Angrilli F; Lazzaro A; Baldini L
Cancer; 2009 May; 115(9):1906-13. PubMed ID: 19248044
[TBL] [Abstract][Full Text] [Related]
2. The role of mitoxantrone in the treatment of indolent lymphomas.
Hagemeister F; Cabanillas F; Coleman M; Gregory SA; Zinzani PL
Oncologist; 2005 Feb; 10(2):150-9. PubMed ID: 15709217
[TBL] [Abstract][Full Text] [Related]
3. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma.
Zinzani PL; Pulsoni A; Perrotti A; Soverini S; Zaja F; De Renzo A; Storti S; Lauta VM; Guardigni L; Gentilini P; Tucci A; Molinari AL; Gobbi M; Falini B; Fattori PP; Ciccone F; Alinari L; Martelli M; Pileri S; Tura S; Baccarani M
J Clin Oncol; 2004 Jul; 22(13):2654-61. PubMed ID: 15159414
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas.
Rohatgi N; LaRocca RV; Bard V; Sethuraman G; Foon KA
Am J Hematol; 2002 Jul; 70(3):181-5. PubMed ID: 12111762
[TBL] [Abstract][Full Text] [Related]
5. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network.
Hainsworth JD; Litchy S; Morrissey LH; Andrews MB; Grimaldi M; McCarty M; Greco FA
J Clin Oncol; 2005 Mar; 23(7):1500-6. PubMed ID: 15632411
[TBL] [Abstract][Full Text] [Related]
6. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Tsimberidou AM; Kantarjian HM; Cortes J; Thomas DA; Faderl S; Garcia-Manero G; Verstovsek S; Ferrajoli A; Wierda W; Alvarado Y; O'Brien SM; Albitar M; Keating MJ; Giles FJ
Cancer; 2003 Apr; 97(7):1711-20. PubMed ID: 12655528
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucémies et Autres Maladies du Sang (GOELAMS).
Morschhauser F; Mounier N; Sebban C; Brice P; Solal-Celigny P; Tilly H; Feugier P; Fermé C; Copin MC; Lamy T
Cancer; 2010 Sep; 116(18):4299-308. PubMed ID: 20549824
[TBL] [Abstract][Full Text] [Related]
8. Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma.
Sacchi S; Pozzi S; Marcheselli R; Federico M; Tucci A; Merli F; Orsucci L; Liberati M; Vallisa D; Brugiatelli M;
Cancer; 2007 Jul; 110(1):121-8. PubMed ID: 17503433
[TBL] [Abstract][Full Text] [Related]
9. Efficacious but insidious: a retrospective analysis of fludarabine-induced myelotoxicity using long-term culture-initiating cells in 100 follicular lymphoma patients.
Janikova A; Koristek Z; Vinklarkova J; Pavlik T; Sticha M; Navratil M; Kral Z; Vasova I; Mayer J
Exp Hematol; 2009 Nov; 37(11):1266-73. PubMed ID: 19654036
[TBL] [Abstract][Full Text] [Related]
10. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone.
Taskinen M; Karjalainen-Lindsberg ML; Nyman H; Eerola LM; Leppä S
Clin Cancer Res; 2007 Oct; 13(19):5784-9. PubMed ID: 17908969
[TBL] [Abstract][Full Text] [Related]
11. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center.
Liu Q; Fayad L; Cabanillas F; Hagemeister FB; Ayers GD; Hess M; Romaguera J; Rodriguez MA; Tsimberidou AM; Verstovsek S; Younes A; Pro B; Lee MS; Ayala A; McLaughlin P
J Clin Oncol; 2006 Apr; 24(10):1582-9. PubMed ID: 16575009
[TBL] [Abstract][Full Text] [Related]
12. High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma.
Montoto S; Moreno C; Domingo-Doménech E; Estany C; Oriol A; Altés A; Besalduch J; Pedro C; Gardella S; Escoda L; Asensio A; Vivancos P; Galán P; de Sevilla AF; Ribera JM; Briones J; Colomer D; Campo E; Montserrat E; López-Guillermo A;
Haematologica; 2008 Feb; 93(2):207-14. PubMed ID: 18223288
[TBL] [Abstract][Full Text] [Related]
13. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma.
Czuczman MS; Koryzna A; Mohr A; Stewart C; Donohue K; Blumenson L; Bernstein ZP; McCarthy P; Alam A; Hernandez-Ilizaliturri F; Skipper M; Brown K; Chanan-Khan A; Klippenstein D; Loud P; Rock MK; Benyunes M; Grillo-Lopez A; Bernstein SH
J Clin Oncol; 2005 Feb; 23(4):694-704. PubMed ID: 15681517
[TBL] [Abstract][Full Text] [Related]
14. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.
Romaguera JE; Fayad L; Rodriguez MA; Broglio KR; Hagemeister FB; Pro B; McLaughlin P; Younes A; Samaniego F; Goy A; Sarris AH; Dang NH; Wang M; Beasley V; Medeiros LJ; Katz RL; Gagneja H; Samuels BI; Smith TL; Cabanillas FF
J Clin Oncol; 2005 Oct; 23(28):7013-23. PubMed ID: 16145068
[TBL] [Abstract][Full Text] [Related]
15. [A clinical observation of fludarabine-containing regimens in the treatment of low grade non-Hodgkin's lymphoma].
Lü SQ; Yang JM; Song XM; Chen L; Zhang WP; Ni X; Xu XQ; Wang JM
Zhonghua Zhong Liu Za Zhi; 2007 Sep; 29(9):710-2. PubMed ID: 18246806
[TBL] [Abstract][Full Text] [Related]
16. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
Tam CS; Wolf M; Prince HM; Januszewicz EH; Westerman D; Lin KI; Carney D; Seymour JF
Cancer; 2006 Jun; 106(11):2412-20. PubMed ID: 16649223
[TBL] [Abstract][Full Text] [Related]
17. [Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
Forstpointner R; Hänel A; Repp R; Hermann S; Metzner B; Pott C; Hartmann F; Rothmann F; Böck HP; Wandt H; Unterhalt M; Hiddemann W
Dtsch Med Wochenschr; 2002 Oct; 127(43):2253-8. PubMed ID: 12397539
[TBL] [Abstract][Full Text] [Related]
18. New treatment options have changed the survival of patients with follicular lymphoma.
Fisher RI; LeBlanc M; Press OW; Maloney DG; Unger JM; Miller TP
J Clin Oncol; 2005 Nov; 23(33):8447-52. PubMed ID: 16230674
[TBL] [Abstract][Full Text] [Related]
19. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma.
McLaughlin P; Hagemeister FB; Rodriguez MA; Sarris AH; Pate O; Younes A; Lee MS; Dang NH; Romaguera JE; Preti AH; McAda N; Cabanillas F
Semin Oncol; 2000 Dec; 27(6 Suppl 12):37-41. PubMed ID: 11225999
[TBL] [Abstract][Full Text] [Related]
20. Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines.
Rigacci L; Mappa S; Nassi L; Alterini R; Carrai V; Bernardi F; Bosi A
Hematol Oncol; 2007 Dec; 25(4):198-203. PubMed ID: 17654614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]